The role of therapy in the outcome of patients with myelofibrosis.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34851
Abstract: BACKGROUND The treatment of patients with myelofibrosis (MF) has evolved in the past decade, as reflected in an increased use of various therapeutic agents that could potentially impact patient outcomes. METHODS In this retrospective study,… read more here.
Keywords: ruxolitinib; therapy outcome; therapy; jak ... See more keywords
Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Immunology"
DOI: 10.1002/eji.202149173
Abstract: Cytokine signaling, especially interferon (IFN) signaling is closely linked to several aspects of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. During initial SARS‐CoV‐2 infection, symptomatic patients present with impaired type I/III IFN‐mediated antiviral responses.… read more here.
Keywords: sars cov; jak; cov infection; janus kinase ... See more keywords
The Rationale for Immunotherapy in Myeloproliferative Neoplasms
Sign Up to like & getrecommendations! Published in 2019 at "Current Hematologic Malignancy Reports"
DOI: 10.1007/s11899-019-00527-7
Abstract: The classic, chronic Philadelphia chromosome negative myeloproliferative neoplasms (MPN)—essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF)—are clonal malignancies of hematopoietic stem cells and are associated with myeloproliferation, organomegaly, and constitutional symptoms. Expanding knowledge that… read more here.
Keywords: rationale immunotherapy; myeloproliferative neoplasms; jak; immunotherapy myeloproliferative ... See more keywords
The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib
Sign Up to like & getrecommendations! Published in 2020 at "Current Hematologic Malignancy Reports"
DOI: 10.1007/s11899-020-00596-z
Abstract: Ruxolitinib is the first FDA-approved JAK inhibitor for the treatment of myeloproliferative neoplasms and is an effective means of controlling symptom burden and improving splenomegaly. However, a majority of patients will develop disease progression with… read more here.
Keywords: pacritinib; jak; generation jak; myeloproliferative neoplasms ... See more keywords
Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
Sign Up to like & getrecommendations! Published in 2020 at "Archives of pharmacal research"
DOI: 10.1007/s12272-020-01282-7
Abstract: JAKs are a family of intracellular tyrosine kinases consisting of four members, JAK1, JAK2, JAK3, and TYK2. They are key components of the JAK-STAT pathway that transmit signals of many cytokines involved in the pathogenesis… read more here.
Keywords: jak; mediated diseases; immune mediated; pseudokinase ... See more keywords
Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "Dermatology and Therapy"
DOI: 10.1007/s13555-021-00596-8
Abstract: Deucravacitinib, a novel, oral, selective inhibitor of tyrosine kinase 2 (TYK2) signaling, acts via an allosteric mechanism by binding to the enzyme’s regulatory domain instead of the catalytic domain. This unique binding provides high functional… read more here.
Keywords: jak; kinase; inhibition; tyk2 ... See more keywords
Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo
Sign Up to like & getrecommendations! Published in 2017 at "Current Dermatology Reports"
DOI: 10.1007/s13671-017-0163-z
Abstract: Purpose of ReviewAlopecia areata (AA) and vitiligo are dermatological autoimmune diseases that, until recently, have had no specifically targeted therapies. Here, we review the future of therapies specifically targeted to the treatment of alopecia areata… read more here.
Keywords: vitiligo; jak; dermatology; treatment ... See more keywords
SnapShot: Jak-STAT Signaling II
Sign Up to like & getrecommendations! Published in 2020 at "Cell"
DOI: 10.1016/j.cell.2020.04.052
Abstract: The JAK-STAT pathway is an evolutionarily conserved signal transduction paradigm, providing mechanisms for rapid receptor-to-nucleus communication and transcription control. Discoveries in this field provided insights into primary immunodeficiencies, inherited autoimmune and autoinflammatory diseases, and hematologic… read more here.
Keywords: stat signaling; jak; snapshot jak; jak stat ... See more keywords
JAK and STAT members in channel catfish: Identification, phylogenetic analysis and expression profiling after Edwardsiella ictaluri infection
Sign Up to like & getrecommendations! Published in 2018 at "Developmental and Comparative Immunology"
DOI: 10.1016/j.dci.2017.12.019
Abstract: &NA; The Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway is one of the main pleiotropic cascades used to transmit information from extracellular receptors to the nucleus, which results in DNA transcription and… read more here.
Keywords: jak; channel catfish; ictaluri infection; jak stat ... See more keywords
Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of pharmacology"
DOI: 10.1016/j.ejphar.2020.173238
Abstract: Rheumatoid arthritis (RA) fibroblast-like synoviocytes (RA-FLS) play a crucial role in the pathogenesis of RA. RA-FLS display passive pro-inflammatory responses and self-directed aggressive responses, such as pro-inflammatory mediator production, reduced apoptosis and formation of a… read more here.
Keywords: jak; stat signaling; role; peficitinib ... See more keywords
Tyrosine Kinase 2 and Janus Kinase‒Signal Transducer and Activator of Transcription Signaling and Inhibition in Plaque Psoriasis.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2021.06.869
Abstract: Plaque psoriasis is a common, chronic, systemic, immune-mediated inflammatory disease. The Janus kinase‒signal transducer and activator of transcription (JAK-STAT) pathway plays a major role in intracellular cytokine signaling in inflammatory processes involved in psoriasis. Although… read more here.
Keywords: jak; plaque psoriasis; signal transducer; kinase signal ... See more keywords